Category: Funding Roundup
California-based CareFusion plans to dole out $100 million for a 40% stake in Israeli infusion pump maker Caesarea Medical Electronics.
CareFusion (NYSE:CFN) announced today that it invested $100 million into Israel-based Caesarea Medical Electronics, taking a 40% stake in the infusion pump company.
Connecticut orthopedics maker Soft Tissue Regeneration is close to tying up a $5 million funding round.
Orthopedics maker Soft Tissue Regeneration is closing in on a $5 million funding round, with $4.7 million raised so far.
The New Haven, Conn.-based company is raising funds through sales of equity, options, warrants and other securities, with 14 unnamed investors listed so far in regulatory filings.
Echo Therapeutics aims to raise up to $15 million in order to help cover costs in bringing its Symphony continuous glucose monitoring system to the market.
Echo Therapeutics (NSDQ:ECTE) is offering 3.2 million shares of its common stock in hopes of raising about $15 million.
Endologix is seeking to raise $75 million through sales of convertible notes with 2018 due dates.
Endologix (NSDQ:ELGX) announced this week that the company is offering $75 million in convertible notes.
C.R. Bard continues to provide medical and surgical supplies to the U.S. Defense Dept. with a $46.3 million extension to its multi-year contract.
Medical device giant C.R. Bard (NYSE:BCR) landed a new $46.3 million contract with the U.S. Defense Dept., extending for a 2nd year a deal to provide the agency with medical supplies.
Trice Orthopedics closes a $3 million bridge loan led by BioStar Ventures.
Trice Orthopedics said it closed a bridge loan financing worth about $3 million.
The King Of Prussia, Pa.-based medical device company said BioStar Ventures led the round, along with Millennium Life Sciences, existing investors and several new private backers.
Xlumena says it closed a $25 million Series C round as it pursues FDA clearance for its Axios stent and delivery system.
Xlumena said it closed a $25 million Series C round it plans to use to expand its commercial footprint and win FDA clearance for its Axios stent and delivery system.